Warning
: your browser is no longer supported.
CLICK HERE
to review the supported browser list.
CLICK HERE
to download a PDF version of this report to read and/or print.
2022 Proxy Statement
Menu
Close
Select Document
✔
{hosting_shortdoctitlestripped}
✔
{doc1_shortdoctitlestripped}
✔
{doc2_shortdoctitlestripped}
✔
{doc3_shortdoctitlestripped}
✔
{doc4_shortdoctitlestripped}
✔
{doc5_shortdoctitlestripped}
✔
{doc6_shortdoctitlestripped}
✔
{doc7_shortdoctitlestripped}
✔
{doc8_shortdoctitlestripped}
✔
{doc9_shortdoctitlestripped}
✔
{doc10_shortdoctitlestripped}
✔
{doc11_shortdoctitlestripped}
✔
{doc12_shortdoctitlestripped}
✔
{doc13_shortdoctitlestripped}
✔
{doc14_shortdoctitlestripped}
✔
{doc15_shortdoctitlestripped}
2022 Proxy Statement
Purpose Blueprint
Table of Contents
A Letter from Pfizer's Chairman & Chief Executive Officer
A Message from Pfizer's Lead Independent Director
Notice of 2022 Annual Meeting and Proxy Statement
2021 Milestones
Our Business and Strategy
Item 1 - Election of Directors
Criteria for Board Membership
Selection of Candidates
Director Independence
Our 2022 Director Nominees
Director Nominees
Governance
Overview
Governance Materials Available on Our Website
Board Leadership Structure
The Board's Role in Risk Oversight
The Board's Role in Succession Planning
Evaluation of Board Effectiveness
Board and Committee Information
Governance & Sustainability Committee Report
Regulatory and Compliance Committee Report
Shareholder Outreach
Public Policy Engagement and Political Participation
Pfizer Policies on Business Conduct
Other Governance Practices and Policies
Non-Employee Director Compensation
2021 Director Compensation Table
Securities Ownership
Beneficial Owners
Item 2 - Ratification of Selection of Independent Registered Public Accounting Firm
Audit and Non-Audit Fees
Audit Committee Report
Item 3 - 2022 Advisory Approval of Executive Compensation
2021 Advisory Vote on Executive Compensation
2021 Pay-for-Performance
2022 Advisory Vote on Executive Compensation
Compensation Committee Report
Executive Compensation
Compensation Discussion and Analysis
Executive Summary
Compensation Tables
Financial Measures
Shareholder Proposals
Item 4 - Amending Proxy Access
Item 5 - Report on Political Expenditures Congruency
Item 6 - Report on Transfer of Intellectual Property to Potential COVID-19 Manufacturers
Item 7 - Report on Board Oversight of Risks Related to Anticompetitive Practices
Item 8 - Report on Public Health Costs of Protecting Vaccine Technology
Annual Meeting Information
Annual Meeting
Voting
Proxy Materials
Other Questions
Other Business
Submitting Proxy Proposals and Director Nominations for the 2023 Annual Meeting
Corporate and Shareholder Information
Meet our Director Nominees
Help & Features
Download PDF
Downloads
Company Home
Share
Print
Clickable Index
Thumbnails
Accessibility Features
Help
Menu
Zoom In
Zoom Out
Zoom In
Help
Help
TOC
TOC
PDF
PDF
Home
Home
Home
Home
Home
Zoom Out
Home
Home
Home
Home
Print
Print
Print
Clickable Index
Clickable Index
Thumbnails
Thumbnails
Help
Help
Unpin Menu Bar
Pin Menu Bar
Go to previous page
Go to previous page
Go to previous page
Go to previous page
Go to next page
Go to next page
Go to next page
Page 86 of 106
Single Page View
Double Page View
...Previous
Continue...
WARNING: JavaScript is disabled.
CLICK HERE
for help.
Click here
for a list of supported browsers.